Viral infection testing and biomarker indicators are developed and utilized throughout the vast majority of the population in the case of identifying the presence of a virus during the preliminary stages of prevention. Tests are developed by utilizing viral antigens on the surface of cells infected with a specific virus. The viral antigen detection test is done with a sample of tissue that could be infected. Antibodies that are tagged (have a dye or tracer to identify as a biomarker) attach to those viral antigens when mixed with the sample to determine if a specimen is positive or not.
The most common test used for viral diagnosis are antigen detection. Methods of antigen detection include fluorescent antibody staining, immuno-peroxidase staining, etc. which are used for identifying positive and negative biomarkers to determine the appearance of a viral infection.
Once a new strain of a virus has been confirmed, it is feasible to immediately develop a complementary viral infection test to prevent the spread of the virus. After these specific tests have been developed, they can be used at the preliminary stages of identification, in order to determine the presence of a new strain of a virus within a given population, to prevent an epidemic.
Using a small subgroup of the population, the tests can be immediately used to determine the percentage infected within a population, to prevent further spread. These tests will also show the percentage of individuals who are asymptomatic, as well as have mild to moderate symptoms upon infection. While testing for virus infections is feasible during the preliminary stages to prevent an epidemic, once the percentage infected surpasses a certain point, it becomes futile. The data accumulated can be used for epidemiological studies but these can again be obtained using a much smaller sample (a hundred). It is far more feasible to test smaller subgroups of the population to obtain statistics and data rather than large ones. The critical point is to identify whether a threshold as been reached, in which the population can resume regular activities without restrictions.
Data Analysis
Additional Percentage Margins to consider regarding testing results can include: %
Percentage Infected %
Percentage Positive %
Percentage Asymptomatic %
Percentage Negative %
New Margin/Mean/Average/Median
Margin for Infected vs. Uninfected Population
Margin for Adaptability into Immune System
Margin for Antibody Presence
Percent Immunity %
Daily/Weekly/Monthly assessment
Cost Assessment Percentage (person/city/state/country)
Cost of Development
Cost of Implementation
Annual Viral Cycle
No comments:
Post a Comment